Literature DB >> 16837498

Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study.

S Furukawa, S Yasuda, O Amengual, T Horita, T Atsumi, T Koike.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16837498      PMCID： PMC1798255          DOI： 10.1136/ard.2005.046870

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

Authors:  U Laufs; V La Fata; J Plutzky; J K Liao
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

2.  The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome.

Authors:  P R Ames; S Lupoli; J Alves; T Atsumi; C Edwards; L Iannaccone; M A Khamashta; G R Hughes; V Brancaccio
Journal:  Br J Rheumatol       Date:  1997-10

3.  Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; K Illingworth; A Blann; C R Hay; S Hollis; M I Jayson
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

4.  HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.

Authors:  T Bourcier; P Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

5.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

6.  Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease.

Authors:  M Greaves; R G Malia; A Milford Ward; J Moult; C M Holt; N Lindsey; P Hughes; M Goodfield; N R Rowell
Journal:  Br J Rheumatol       Date:  1988-08

7.  Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.

Authors:  M B Kahaleh; I Osborn; E C LeRoy
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

8.  Endothelial injury in scleroderma.

Authors:  M B Kahaleh; G K Sherer; E C LeRoy
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307
  8 in total
  14 in total

Review 1.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

Review 2.  Novel paradigm for treating vasculopathy in systemic sclerosis: vascular progenitor cells and statins.

Authors:  Monique Hinchcliff; John Varga
Journal:  Curr Rheumatol Rep       Date:  2007-04       Impact factor: 4.592

Review 3.  Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

Review 4.  A vascular mechanistic approach to understanding Raynaud phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Nat Rev Rheumatol       Date:  2014-12-23       Impact factor: 20.543

Review 5.  Systemic sclerosis--challenges for clinical practice.

Authors:  Zsuzsanna H McMahan; Laura K Hummers
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

Review 6.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

Review 7.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 8.  Statins and autoimmunity.

Authors:  Saakshi Khattri; Gisele Zandman-Goddard
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

9.  Circulating Thrombotic Risk Factors in Young Patients with Coronary Artery Disease Who Are on Statins and Anti-platelet Drugs.

Authors:  Reema George; Harikrishnan Sivadasanpillai; Narayani Jayakumari; Anugya Bhatt; Jissa V Thulaseedharan; Jaganmohan A Tharakan
Journal:  Indian J Clin Biochem       Date:  2015-12-22

Review 10.  Statins and the vascular endothelial inflammatory response.

Authors:  John Greenwood; Justin C Mason
Journal:  Trends Immunol       Date:  2007-01-02       Impact factor: 16.687
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.